Agilent Technologies (NYSE:A) Price Target Raised to $185.00

Agilent Technologies (NYSE:A) had its price objective hoisted by Royal Bank Of Canada from $155.00 to $185.00 in a report released on Thursday morning,Benzinga reports. The brokerage currently has an outperform rating on the medical research company’s stock.

A has been the subject of a number of other reports. Robert W. Baird lifted their price objective on shares of Agilent Technologies from $155.00 to $156.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 26th. Wolfe Research reaffirmed a “hold” rating on shares of Agilent Technologies in a report on Tuesday, June 2nd. Jefferies Financial Group initiated coverage on Agilent Technologies in a research report on Thursday, July 9th. They issued a “hold” rating and a $135.00 price target for the company. HSBC reduced their price objective on Agilent Technologies from $180.00 to $165.00 and set a “buy” rating on the stock in a research note on Wednesday, June 3rd. Finally, Wells Fargo & Company decreased their price objective on Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating on the stock in a research report on Thursday, May 28th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, Agilent Technologies has a consensus rating of “Moderate Buy” and a consensus target price of $170.33.

Agilent Technologies Price Performance

NYSE:A opened at $154.47 on Thursday. The business’s 50-day moving average is $140.30 and its 200 day moving average is $127.04. Agilent Technologies has a 12 month low of $108.35 and a 12 month high of $163.75. The company has a market capitalization of $43.63 billion, a P/E ratio of 30.41, a P/E/G ratio of 2.65 and a beta of 1.25. The company has a current ratio of 2.05, a quick ratio of 1.62 and a debt-to-equity ratio of 0.50.

Agilent Technologies (NYSE:A) last released its quarterly earnings results on Wednesday, August 26th. The medical research company reported $1.62 earnings per share for the quarter, beating the consensus estimate of $1.49 by $0.13. Agilent Technologies had a return on equity of 24.45% and a net margin of 19.53%.The business had revenue of $1.88 billion during the quarter, compared to analysts’ expectations of $1.84 billion. During the same quarter last year, the business posted $1.37 EPS. The firm’s revenue for the quarter was up 8.1% compared to the same quarter last year. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. On average, equities research analysts forecast that Agilent Technologies will post 6.2 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Mitsubishi UFJ Asset Management Co. Ltd. raised its position in shares of Agilent Technologies by 4.3% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 599,581 shares of the medical research company’s stock worth $82,712,000 after acquiring an additional 24,687 shares in the last quarter. Bank of Nova Scotia bought a new stake in Agilent Technologies during the second quarter valued at about $58,539,000. Dudley & Shanley Inc. boosted its position in Agilent Technologies by 25.9% during the second quarter. Dudley & Shanley Inc. now owns 69,500 shares of the medical research company’s stock valued at $9,232,000 after purchasing an additional 14,300 shares in the last quarter. BIP Wealth LLC purchased a new position in Agilent Technologies in the second quarter valued at about $834,000. Finally, Crossmark Global Holdings Inc. grew its stake in Agilent Technologies by 39.6% in the fourth quarter. Crossmark Global Holdings Inc. now owns 33,918 shares of the medical research company’s stock valued at $4,615,000 after purchasing an additional 9,615 shares during the last quarter.

Key Headlines Impacting Agilent Technologies

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Agilent reported fiscal Q3 earnings of $1.62 per share, above the $1.48-$1.49 analyst consensus, while revenue of approximately $1.88 billion also exceeded expectations. EPS increased from $1.37 a year earlier, supporting the view that profitability is improving. Agilent Technologies Q3 Earnings and Revenues Top Estimates
• Positive Sentiment: Management raised its full-year guidance following the strong quarter. Commentary highlighted product momentum, a recovery in China, improving demand and expanding margins, all of which could support additional earnings growth. Agilent Technologies Lifts Outlook After Strong Quarter
• Positive Sentiment: Several major firms raised their price targets and maintained bullish ratings after the results. Targets now range from $175 to $190, with upgrades from JPMorgan, Citi, Barclays, Goldman Sachs, Bank of America, Stifel, TD Cowen, Bernstein and RBC. Analysts Raise Agilent Technologies Price Targets
• Neutral Sentiment: Despite the improved outlook, valuation remains relatively demanding: Agilent trades at roughly 30 times earnings, with a PEG ratio above 2.7. This leaves the stock sensitive to any slowdown in demand or disappointment in future guidance.

About Agilent Technologies

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.